JP2020536869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536869A5 JP2020536869A5 JP2020519286A JP2020519286A JP2020536869A5 JP 2020536869 A5 JP2020536869 A5 JP 2020536869A5 JP 2020519286 A JP2020519286 A JP 2020519286A JP 2020519286 A JP2020519286 A JP 2020519286A JP 2020536869 A5 JP2020536869 A5 JP 2020536869A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- drug
- combination
- agent
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 17
- 229940000425 combination drug Drugs 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 2
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 2
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 claims 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- -1 Semakusanibu Chemical compound 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 229960003784 lenvatinib Drugs 0.000 claims 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 1
- 229950011068 niraparib Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229950000578 vatalanib Drugs 0.000 claims 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569239P | 2017-10-06 | 2017-10-06 | |
| US62/569,239 | 2017-10-06 | ||
| PCT/US2018/054606 WO2019071123A1 (en) | 2017-10-06 | 2018-10-05 | POLYRHEERAPIES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536869A JP2020536869A (ja) | 2020-12-17 |
| JP2020536869A5 true JP2020536869A5 (https=) | 2021-11-11 |
Family
ID=64051695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519286A Pending JP2020536869A (ja) | 2017-10-06 | 2018-10-05 | 併用療法およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11801240B2 (https=) |
| EP (1) | EP3691685A1 (https=) |
| JP (1) | JP2020536869A (https=) |
| KR (1) | KR20200067164A (https=) |
| CN (1) | CN111182923A (https=) |
| AU (2) | AU2018346688A1 (https=) |
| BR (1) | BR112020006845A2 (https=) |
| CA (1) | CA3076859A1 (https=) |
| CL (2) | CL2020000907A1 (https=) |
| CO (1) | CO2020005223A2 (https=) |
| EA (1) | EA202090655A1 (https=) |
| IL (1) | IL273510A (https=) |
| MA (1) | MA50618A (https=) |
| MX (1) | MX2020003799A (https=) |
| PH (1) | PH12020550400A1 (https=) |
| SG (1) | SG11202002499TA (https=) |
| WO (1) | WO2019071123A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| MX2020005659A (es) * | 2017-12-06 | 2020-08-20 | Jiangsu Hengrui Medicine Co | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. |
| WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
| CN112007042B (zh) * | 2020-09-10 | 2023-02-21 | 中国医学科学院医学生物学研究所 | 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用 |
| CN112316149A (zh) * | 2020-11-11 | 2021-02-05 | 王海涛 | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 |
| NZ801252A (en) * | 2020-11-27 | 2026-03-27 | Snbioscience Inc | Pharmaceutical composition comprising insoluble camptothecin compound-containing nanoparticle for treatment of cancer and combination therapy thereof |
| KR20220085742A (ko) * | 2020-12-15 | 2022-06-22 | 칸트사이언스 주식회사 | 암 환자에서 혈관 신생 억제 및 항암제 치료 효과 증대용 조성물 |
| CN114748479B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
| ES3057099T3 (en) * | 2021-01-18 | 2026-02-26 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| CN115177621B (zh) * | 2021-04-02 | 2023-09-01 | 上海市第一人民医院 | Av-951在制备用于抑制或治疗甲状腺相关眼病的药物中的应用 |
| CN113101288B (zh) * | 2021-05-08 | 2026-03-31 | 中国人民解放军空军军医大学 | 一种协同增效治疗脊索瘤的组合药物及其用途 |
| CN118434411A (zh) * | 2021-12-23 | 2024-08-02 | 波士顿科学医疗设备有限公司 | 化学栓塞组合物及其治疗方法 |
| CN116077643B (zh) * | 2021-12-31 | 2025-02-11 | 成都金瑞基业生物科技有限公司 | 治疗和/或预防肺癌的联合用药物及应用 |
| CN114712515A (zh) * | 2022-03-30 | 2022-07-08 | 上海交通大学医学院附属瑞金医院 | 一种dll4抑制剂联合parp抑制剂在制备治疗卵巢癌药物中的应用 |
| CN115177594B (zh) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | 一种阿昔替尼药物制剂及其制备方法 |
| CN115154589B (zh) * | 2022-08-26 | 2024-04-09 | 山东大学 | 白藜芦醇联合成纤维细胞生长因子1在缓解蒽环类药物诱导的心脏及肝脏毒性中的应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| CA1329771C (en) | 1988-09-01 | 1994-05-24 | Shoji Kishimoto | Angiogenesis inhibitory agent |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2217244A4 (en) | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| WO2009087474A2 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN102307475A (zh) | 2009-02-04 | 2012-01-04 | 彼帕科学公司 | 用与生长因子抑制剂组合的parp抑制剂治疗肺癌 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP3012329B1 (en) | 2010-06-18 | 2017-10-25 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| WO2015116868A2 (en) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| WO2015184145A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
| US20210322415A1 (en) * | 2016-02-15 | 2021-10-21 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210106574A1 (en) | 2017-12-27 | 2021-04-15 | Tesaro, Inc. | Methods of Treating Cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-10-05 EA EA202090655A patent/EA202090655A1/ru unknown
- 2018-10-05 CA CA3076859A patent/CA3076859A1/en active Pending
- 2018-10-05 MA MA050618A patent/MA50618A/fr unknown
- 2018-10-05 KR KR1020207012376A patent/KR20200067164A/ko not_active Ceased
- 2018-10-05 EP EP18796190.9A patent/EP3691685A1/en not_active Withdrawn
- 2018-10-05 JP JP2020519286A patent/JP2020536869A/ja active Pending
- 2018-10-05 US US16/754,083 patent/US11801240B2/en active Active
- 2018-10-05 MX MX2020003799A patent/MX2020003799A/es unknown
- 2018-10-05 WO PCT/US2018/054606 patent/WO2019071123A1/en not_active Ceased
- 2018-10-05 CN CN201880065336.2A patent/CN111182923A/zh active Pending
- 2018-10-05 BR BR112020006845-4A patent/BR112020006845A2/pt not_active Application Discontinuation
- 2018-10-05 SG SG11202002499TA patent/SG11202002499TA/en unknown
- 2018-10-05 AU AU2018346688A patent/AU2018346688A1/en not_active Abandoned
-
2020
- 2020-03-23 IL IL273510A patent/IL273510A/en unknown
- 2020-04-03 CL CL2020000907A patent/CL2020000907A1/es unknown
- 2020-04-03 PH PH12020550400A patent/PH12020550400A1/en unknown
- 2020-04-27 CO CONC2020/0005223A patent/CO2020005223A2/es unknown
- 2020-11-13 CL CL2020002958A patent/CL2020002958A1/es unknown
-
2022
- 2022-03-21 AU AU2022201944A patent/AU2022201944A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536869A5 (https=) | ||
| JP2020536066A5 (https=) | ||
| Yi et al. | Combination strategies with PD-1/PD-L1 blockade: current advances and future directions | |
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| Li et al. | Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges | |
| Zirlik et al. | Anti-angiogenics: current situation and future perspectives | |
| Morgan et al. | Improving the efficacy of chemoradiation with targeted agents | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| Cosmai et al. | Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) | |
| Vici et al. | Emerging biological treatments for uterine cervical carcinoma | |
| JP2017533266A5 (https=) | ||
| JP2020522486A5 (https=) | ||
| HRP20251050T1 (hr) | Ciklični dinukleotidi za liječenje stanja povezanih s aktivnošću sting kao što je rak | |
| Rogosin et al. | Beyond bevacizumab: antiangiogenic agents | |
| Chi et al. | Antiangiogenic strategies for treatment of malignant gliomas | |
| Okines et al. | Current perspective: bevacizumab in colorectal cancer–a time for reappraisal? | |
| Jhaveri et al. | Abstract OT-03-05: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) | |
| JP2023510853A5 (https=) | ||
| Bertino et al. | Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer | |
| Baek et al. | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer | |
| Chhatrala et al. | Targeted therapy in gastrointestinal malignancies | |
| Casari et al. | Novel treatment options in metastatic esophageal carcinoma: checkpoint inhibitors in combination therapies | |
| Georgiev et al. | New pharmacological approaches in the treatment of oncological diseases | |
| Tahara | Secondary Publication: Molecularly Targeted Therapeutic Drug Treatment in Gastroenterology | |
| Kang et al. | Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials |